(VIANEWS) – CONTEXTVISION (CONTX.OL) is among this list of stock assets with the highest dividend rate and return on equity on the Healthcare sector.
| Financial Asset | Price | Forward Dividend Yield | Return on Equity |
|---|---|---|---|
| CONTEXTVISION (CONTX.OL) | kr7.28 | 3.46% | 61.1% |
| BOIRON (BOI.PA) | €40.10 | 2.76% | 8.64% |
| MEDISTIM (MEDI.OL) | kr207.00 | 2.25% | 32.37% |
Several Euronext companies pay out dividends to its shareholders. The dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.
1. CONTEXTVISION (CONTX.OL)
3.46% Forward Dividend Yield and 61.1% Return On Equity
ContextVision AB (publ), a medical technology software company, provides image analysis and imaging for medical systems in Asia, Europe, and the United States. The company offers image enhancement software for 2D/3D/4D ultrasound, radiography, magnetic resonance imaging (MRI), and veterinary. Its products include Rivent that offers unparalleled image quality for various types of ultrasound systems for women's health, general imaging, cardiovascular, and point of care applications; Rivent Mobile, an enhancing ultrasound image for the handheld ultrasound devices using mobile phones and tablets; and Rivent 3D, an image enhancement product for 3D ultrasound. The company also provides Altumira/Altumira Plus, a platform for digital radiography; and Orthopedic Package for orthopedic imaging. In addition, it offers GOPView MRI2Plus, an image enhancement solution for MRI. The company was founded in 1983 and is headquartered in Stockholm, Sweden.
Earnings Per Share
As for profitability, CONTEXTVISION has a trailing twelve months EPS of kr0.48.
PE Ratio
CONTEXTVISION has a trailing twelve months price to earnings ratio of 15.17. Meaning, the purchaser of the share is investing kr15.17 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 61.1%.
Volume
Today’s last reported volume for CONTEXTVISION is 37186 which is 1.36% above its average volume of 36684.
Yearly Top and Bottom Value
CONTEXTVISION’s stock is valued at kr7.28 at 16:30 EST, below its 52-week low of kr7.80.
Volatility
CONTEXTVISION’s last week, last month’s, and last quarter’s current intraday variation average was a negative 0.47%, a negative 0.04%, and a positive 1.96%.
CONTEXTVISION’s highest amplitude of average volatility was 0.84% (last week), 1.54% (last month), and 1.96% (last quarter).
Dividend Yield
According to Morningstar, Inc., the next dividend payment is on Nov 2, 2023, the estimated forward annual dividend rate is 0.3 and the estimated forward annual dividend yield is 3.46%.
More news about CONTEXTVISION.
2. BOIRON (BOI.PA)
2.76% Forward Dividend Yield and 8.64% Return On Equity
Boiron SA manufactures and sells homeopathic medicines in France, rest of Europe, North America, and internationally. The company offers non-proprietary homeopathic medicines and homeopathic specialties; and other healthcare products include medical devices, invitro diagnostics, dietary supplements, cosmetics, and phytotherapy. It also provides homeopathic specialties comprising Oscillococcinum to treat influenza symptoms, such as fever, chills, headaches, and aches; Stodal and Stodaline for treating coughs; Arnigel for adjunctive local treatment of benign trauma in the absence of open wounds; Camilia for the treatment of teething problems for babies; Sédatif PC to treat anxiety and emotional, and minor sleep disorders; Coryzalia for the treatment of cold symptoms and rhinitis; Homéoptic to treat eye discomfort and irritation due to various causes for adults and children; Homéovox for vocal disorders; Homéoplasmine for treating irritated skin and redness; Varésol to treat symptoms of chickenpox; and Arnicare Arthritis for use in the treatment of benign trauma pain. In addition, it offers Dermoplasmine, a plant based multi-use balm that repairs and protects irritated and damaged skin; COVID self-tests and rapid antigenic tests; LABIAMEO, that used to treat outbreaks of localized cold sores; and CONVAMEO to treat physical and mental asthenia. The company offers its products through distribution centers, pharmacies, pharmacy chains, wholesalers, grocery and drugstores, health food stores, and online retail. Boiron SA was founded in 1932 and is headquartered in Messimy, France.
Earnings Per Share
As for profitability, BOIRON has a trailing twelve months EPS of €2.74.
PE Ratio
BOIRON has a trailing twelve months price to earnings ratio of 14.64. Meaning, the purchaser of the share is investing €14.64 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 8.64%.
Dividend Yield
As claimed by Morningstar, Inc., the next dividend payment is on Oct 18, 2023, the estimated forward annual dividend rate is 1.1 and the estimated forward annual dividend yield is 2.76%.
Revenue Growth
Year-on-year quarterly revenue growth declined by 6.6%, now sitting on 517.36M for the twelve trailing months.
Volume
Today’s last reported volume for BOIRON is 4139 which is 66.14% below its average volume of 12225.
More news about BOIRON.
3. MEDISTIM (MEDI.OL)
2.25% Forward Dividend Yield and 32.37% Return On Equity
Medistim ASA develops, produces, services, leases, and distributes medical devices for cardio-vascular surgery in the United States, Europe, Asia, and internationally. It offers MiraQ Cardiac, a system that combines ultrasound imaging and transit time flow measurement (TTFM) in a single system for cardiac surgery; MiraQ Vascular, a system that combines ultrasound imaging and transit TTFM in a single system for vascular surgery; and imaging probes for intraoperative use. The company also provides various flow probes, such as QuickFit TTFM probes to accurately measure blood volume flow intraoperatively in various range of surgical applications; Vascular TTFM probes for enhancing surgical outcomes; and doppler probes that are used on the surface of the heart/vessel to search for intramural coronary arteries or to locate the position and quantify the degree of a stenosis. In addition, it distributes and sells third party medical equipment. The company was incorporated in 1984 and is headquartered in Oslo, Norway.
Earnings Per Share
As for profitability, MEDISTIM has a trailing twelve months EPS of kr6.41.
PE Ratio
MEDISTIM has a trailing twelve months price to earnings ratio of 32.29. Meaning, the purchaser of the share is investing kr32.29 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 32.37%.
Moving Average
MEDISTIM’s worth is higher than its 50-day moving average of kr202.38 and way under its 200-day moving average of kr242.62.
Volatility
MEDISTIM’s last week, last month’s, and last quarter’s current intraday variation average was a negative 0.34%, a positive 0.34%, and a positive 2.07%.
MEDISTIM’s highest amplitude of average volatility was 1.66% (last week), 2.66% (last month), and 2.07% (last quarter).
Earnings Before Interest, Taxes, Depreciation, and Amortization
MEDISTIM’s EBITDA is 6.72.
More news about MEDISTIM.
